CRISPR Therapeutics (NASDAQ: CRSP) is a pioneering biotech company, but it isn't yet a profitable one. That's why its shares ...

A research team has discovered an enhanced CRISPR gene-editing system that could enable targeted delivery inside the human ...

CEO Sam Kulkarni told investors at the Needham Healthcare Conference that the company is moving into what he described as a ...

Recent commentary has highlighted CRISPR Therapeutics’ expanding gene-editing pipeline, including cardiovascular candidates like CTX310 and CTX320 and programs in type 1 diabetes, alongside fresh Buy ...

NIH-funded UT team and colleagues from Metagenomi Thereapeutics discovered highly efficient enzyme could enable targeted gene editing within the human body.

In heart failure, the heart can no longer supply the body with enough blood. The condition often develops over many years, ...

The rapid evolution of CRISPR/Cas genome editing has redefined the possibilities of cellular and gene therapy, enabling ...

Colossal Biosciences is establishing standards for how biotechnology can responsibly support biodiversity conservation in an ...

When CRISPR cuts a gene flanked by short, repeating DNA sequences, the cell’s repair machinery gets confused. It simply zips ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the stocks that could 10x over the next 10 years. Piper Sandler boosted its ...

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...